“Personal importation” sounds like a category of permission. In the documents that define it, it is a description of when federal inspectors may decline to act. The policy lives in an internal procedures manual, the statute underneath it prohibits rather than allows, and the conditions that trigger the more permissive reading were written for a situation that a marketed, approved weight-loss drug does not match. What arrives instead of permission is set out below, alongside the seizure record — and the assay evidence on what the gray market actually ships is a separate matter, covered in the gray-market article.
What the manual says, in its own words
The relevant text is the Regulatory Procedures Manual, chapter 9, document MAN-000012, version 05, dated March 2024. For personal shipments of drugs that appear violative, it directs that FDA personnel “will use their discretion to decide on a case by case basis whether to detain, refuse, or allow entry.” It then lists two situations in which staff “may consider a more permissive decision.” The first is where the intended use is identified, is not for treatment of a serious condition, and the product is not known to represent a significant health risk.[1]
The second is the one usually invoked, and it has four parts, all of which must hold together: the intended use is unapproved and for a serious condition for which effective treatment may not be available domestically either through commercial or clinical means; there is no known commercialization or promotion to persons residing in the U.S. by those distributing the product; the product is considered not to represent an unreasonable risk; and the individual affirms in writing that it is for the patient’s own use, generally not more than a three month supply, providing either the name and address of a doctor licensed in the U.S. responsible for the treatment, or evidence that the product continues a treatment begun in a foreign country.[1]
The chapter opens by saying what it is not. “The statements in this chapter are intended only to provide operating procedures for FDA personnel and are not intended to create or confer any rights, privileges, or benefits on or for any private person.”[1] FDA’s consumer-facing page, current as of August 18, 2025, is blunter still: “In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use,” and “if a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import.”[2]
The condition an approved drug cannot satisfy
Read the second branch against this particular class. Its first requirement is that effective treatment may not be available domestically. Semaglutide and tirzepatide are approved, labeled and commercially marketed in the United States; the shortages that once constrained supply were declared resolved, which is the subject of the shortage article. Its second requirement is that there be no known commercialization or promotion to persons residing in the U.S. — a condition a foreign seller who advertises to Americans in English defeats by existing. The first branch is no easier: it applies where the use is not for a serious condition, which is not how obesity or type 2 diabetes is characterized by the people seeking treatment for them.
The policy, in other words, was drafted around unavailability. This is a category of drug defined by being available and expensive, and price is not one of the four conditions. Why the domestic figure varies as much as it does is a different question, answered in the pricing article.
The statute underneath the policy
21 U.S.C. 381(d)(1)(A) states that, with narrow exceptions, “no drug subject to section 353(b) of this title or composed wholly or partly of insulin which is manufactured in a State and exported may be imported into the United States unless the drug is imported by the manufacturer of the drug.” The Secretary may authorize an otherwise prohibited importation only where the drug “is required for emergency medical care.”[3]
Section 384 is the importation chapter, and its subsection (j) is captioned “Waiver authority for importation by individuals” — a waiver of a prohibition, not a right. Congress declares there that the Secretary should focus enforcement on cases posing a significant threat to public health and exercise discretion where importation is clearly for personal use and the drug does not appear to present an unreasonable risk; the Secretary may grant waivers by regulation or case by case. A separate paragraph directs the Secretary to grant, by regulation, a waiver for a drug imported from a licensed pharmacy in Canada for personal use in quantities not exceeding a 90-day supply, accompanied by a copy of a valid prescription, from a seller registered with the Secretary, and approved by the Secretary under subchapter V.[4] Every operative verb in that paragraph describes something the Secretary must do, not something an individual may do.
The state import programs are not a consumer channel
Section 804 authorizes states to run wholesale importation programs, and two have been authorized: Florida in January 2024 and Colorado in June 2026. The statute defines “importer” to mean “a pharmacist or wholesaler,” so an individual is not a participant in it at all.[4] The authorization letters require the importer to file a Pre-Import Request that FDA must grant before any eligible drug may be imported, and limit arrival to a single authorized port.[5]
Nor has the mechanism produced a shipment. FDA’s letter of May 6, 2026 records that Florida’s authorization was conditioned on the importer filing an electronic import entry, that three extensions had already been granted, and that FDA was granting “an additional 6-month extension for you to begin implementing your SIP,” to November 6, 2026.[5] Two years and four extensions after authorization, the program had not yet begun.
An import alert switches the discretion off
The manual contains a sentence that overrides much of the rest: “Generally, drugs, biologics, and devices subject to Import Alerts are not amenable to these procedures.”[1] Two alerts matter here. Import alert 66-57 covers foreign-manufactured unapproved prescription drugs distributed to individuals, and reaches all dosage forms and shipments, commercial and personal, from distributors named on its list, including online pharmacies.
Import alert 66-80, published August 21, 2026, is specific to this class and is structured unusually. It carries no red list: detention without physical examination is the default for GLP-1 bulk drug substances, and only firms on a green list are excluded. The alert records that FDA conducted onsite inspections and remote regulatory assessments of 48 GLP-1 active pharmaceutical ingredient sites, and that 21% were noncompliant under section 501 of the act, either because their responses to records requests evidenced noncompliance with manufacturing practice or because they did not respond in time.[6] That alert governs bulk ingredient rather than finished pens, and it is the ingredient supply behind compounded product that it touches — the subject of the article on vial contents.
The counterfeits that reached Americans came through the regulated chain
The intuitive picture puts falsified product at the border and genuine product inside it. The seizure record inverts that. FDA’s standing statement on counterfeit Ozempic carries three dated entries. In December 2023 the agency had seized thousands of units labeled with lot number NAR0074 and serial number 430834149057 from the legitimate U.S. supply chain; analysis found the needles were also counterfeit, so their sterility could not be confirmed, and five adverse events from that lot were known. In April 2025, several hundred units labeled PAR0362 were identified and seized. In December 2025, dozens of units labeled PAR1229 — an authentic lot number — were seized, distinguishable from genuine product only by the position of the EXP/LOT text on the label.[7]
The World Health Organization reached the same conclusion from outside. Its Medical Product Alert No. 2/2024, issued 19 June 2024, covers three falsified batches of Ozempic detected in Brazil in October 2023, the United Kingdom in October 2023 and the United States in December 2023, and states that the product “was supplied in the regulated supply chain.” One batch number was unrecognized, one was genuine on a falsified product, and one carried a serial number not matching manufacturing records.[8] None of that makes an imported supply safer; it means the risk being escaped is also present at home, and the red flags that separate a legitimate seller from a fraudulent one are listed in the red flags article.
What a foreign retail counter looks like when it is sampled
There is no published assay study of GLP-1 pens obtained by personal importation into the United States. There is one rigorous measurement of the adjacent channel. An ethnographic and drug-checking study visited 40 pharmacies across four cities in northern Mexico serving English-speaking visitors. One or more requested controlled substances could be obtained without a prescription at 28 (70.0%) of them; counterfeit pills were obtained at 11 (27.5%); and of 45 samples sold as single pills, 18 were counterfeit, including 7 of 11 sold as one stimulant that contained methamphetamine and 8 of 27 sold as an opioid that contained fentanyl.[9]
The finding that transfers is not the drug class, which is different, but the detection problem: the authors report it was not possible to distinguish counterfeit from authentic medication by the appearance of the pills or the location of the pharmacy, because identical-looking versions were sold in close proximity. A licensed storefront is not an assay.
How common the practice is, and how little is known about it
The best US prevalence work predates this drug class entirely. Using National Health Interview Survey data from 2011 and 2012, a validated index found personal prescription drug importation reported by 0.32% of adults with the fewest risk factors, rising through 0.57%, 1.09% and 2.95% to 13.67% among those with seven or more, with C-statistics of 0.78 in development and 0.76 in validation.[10] The practice was concentrated, not general — and that measurement is more than a decade old.
Several things could not be established. No FDA or Customs figure for mail-facility examinations or refused drug shipments more recent than a 2019 agency presentation was located. No count of GLP-1-specific personal importations exists in any source read here. Neither semaglutide nor tirzepatide appears on the red list of any import alert examined. And nothing above is advice: it is what the manual, the statute, the alerts and the seizure notices say, which readers can open for themselves. How each figure was established before publication is described in the methodology.